Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.06.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Fausto Petrelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, ASST Bergamo Ovest, Treviglio (BG), Italy. Electronic address: faupe@libero.it. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: In metastatic RAS wild-type colorectal cancer (CRC), induction combination chemotherapy doublets (CT) with an anti-EGFR agent are considered the primary treatment. We performed a network meta-analysis (NMA) to compare the relative efficacy of different maintenance treatments for advanced RAS wild-type CRC. MATERIALS AND METHODS: PubMed, EMBASE and Cochrane, from database inception until December 2021 were used. Randomized clinical trials enrolling adults with advanced RAS wild-type CRC and providing overall survival (OS) and/or progression-free survival (PFS) data PRISMA guidelines for NMA were followed. Between-group comparisons were estimated using hazard ratios (HRs) with 95% credible intervals (95% CrIs). Agents were ranked using surface under the cumulative ranking (SUCRA) probabilities. RESULTS: A total of 7 randomized phase 2 trials were included (for a total of 1286 patients). Compared to depotentiation treatments, continuous CT + anti-EGFR was not significantly superior to other maintenance regimens for OS and was ranked as the best option for NMA (SUCRA p-score=0.69). Conversely, in the PFS analysis, single-agent fluoropyrimidines + anti-EGFR was ranked as the best treatment (SUCRA p-score=0.60). CONCLUSIONS: Maintaining chemotherapy doublet + anti-EGFR until progression appears to be the best first-line strategy in terms of OS for advanced unresectable RAS wild-type mCRC treatment. However, fluoropyrimidines single-agent + cetuximab or panitumumab represent a reasonable choice regarding PFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, ASST Bergamo Ovest, Treviglio (BG), Italy. Electronic address: faupe@libero.it.
- Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.
- Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
- Oncology Unit, casa di cura Igea, Milano, Italy.
Zitieren
APA
Petrelli, F., Cherri, S., Ghidini, M., Tomasello, G., Ghidini, A., & Zaniboni, A. (2024). Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.06.008
Vancouver
Petrelli F, Cherri S, Ghidini M, Tomasello G, Ghidini A, Zaniboni A. Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.06.008
BibTeX
@article{Petrelli2024,
author = {Petrelli, Fausto and Cherri, Sara and Ghidini, Michele and Tomasello, Gianluca and Ghidini, Antonio and Zaniboni, Alberto},
title = {Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.06.008}
}
EUVIMED